Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Canc... ( SAN DIEGO Jan. 28 /- Cylene Pharm...)

Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology

Date:1/28/2008

SAN DIEGO, Jan. 28 /PRNewswire/ -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening can
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
6. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
7. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
8. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
9. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
10. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products

Post Your Comments:

(Date:12/2/2009)... , JERUSALEM, Israel, December 2 /P...ility study evaluating the preclinical (animal stu...which combines technology from Weill,Cornell Medic...otential to,treat inherited anemias such as Cooley...series of technologies to expand, ex vivo,populat...

(Date:12/2/2009)... , QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ ... (the "Company"), a global biopharmaceutical compa...y announced that the U.S. Food and Drug Administra...the Company,s PI3K/Akt pathway inhibitor compound,...sed/refractory multiple myeloma. Keryx Biopharmace...

(Date:12/1/2009)... Dr. Kerry Solomon announced t...has launched his redesigned website at www.DrKerr...ulting Group. Dr. Solomon is a proven LASIK, lens... professionally recognized for his substantial con... He is a member of Trusted LASIK Surgeons, which ...

(Date:12/1/2009)... , NEW YORK, Dec. 1 Repo...report is available in its catalogue: ,, Emerg...ket dynamics and the changing healthcare and regul...com/p0165658/Emerging-Clinical-Trial-Locations---E...lthcare-and-regulatory-environment.html ,, Ove...

Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3 AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2 AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5 Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7 Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8

[0] Gamida Cell Announces Feasibility Study With Weill Cornell Medical College [0] AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma [0] Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com [0] Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment

...rsity of Technology (TU/e) have developed an entir...r the first time they used mechanical forces to co...tal concepts in chemistry. This allowed them to in...his discovery paves the way to developing material...nce of mechanical tension. The results of their re...

...er Life Sciences, Inc. (Nasdaq: CALP ) today ann...s will be held on June 2, 2009, at 10:00 a.m. loca...pkinton, Massachusetts. The record date for Calip...s April 16, 2009. , , About Caliper Life Sci...er of cutting-edge technologies enabling researche...

...pril 6 Today, Pepscan reports,that it has achieve...of its,CLIPS-based synthetic peptide immunogen tec...e ligand binding-site on CXCR7 it has induced func... GPCR target CXCR7. CXCR7 is novel,therapeutic tar..., "We are proud and confident with achieving t...

Other Biology Technology:A molecular ripcord for chemical reactions 2 Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7 2

A molecular ripcord for chemical reactions Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7

(Date:12/2/2009)... study results strengthen the evidence that people...ave an increased risk for developing colorectal ca... , "This provides one more reason not to smoke,...or Michael J. Thun, M.D., M.S., vice president eme...he American Cancer Society. "Colorectal cancer sho...

(Date:12/2/2009)...xposure to secondhand smoke for a prolonged period...k of breast cancer, even in women who never smoked...her exposure to side-stream smoke could increase r...aid Peggy Reynolds, Ph.D., senior research scienti...eley office. "While no single epidemiologic study ...

(Date:12/2/2009)...the University of Georgia College of Veterinary Me...at could open new avenues for treating Ichthyophth...celled protozoan parasite that commonly attacks fr...quencing, researchers found that Ich harbors two a...roides, which are usually found free-living, and R...

[0] Cigarette smoking increases colorectal cancer risk [0] Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life [0] UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich'

...et was launched simultaneously by Global Carbon Pr...ris Observatory, and in the USA at Capitol Hill, W... , The Global Carbon Project posted the most recen...understanding the balance of carbon added to the a...te change. Despite the increasing international se...

...h the most commonly performed weight-loss surgery ... developing a rare but serious complication, accor...on of the Journal of Robotic Surgery. , Minimal...dical School at Houston statistically analyzed ope...tions in 605 patients who either underwent laparos...

...y of Colorado at Boulder reveals that air quality ...rce of fine, organic particle pollutants that cont... Los Angeles region. , According to the study, a ...reviously thought is directly emitted by vehicles ...ine, organic particle pollutants form when reactiv...

Other Biology News:Growth in the global carbon budget 2 Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2 CU-Boulder study suggests air quality regulations miss key pollutants 2

Growth in the global carbon budget Robotic surgery lowers risk of a rare but serious complication of gastric bypass CU-Boulder study suggests air quality regulations miss key pollutants

Nitrite Colorimetric Assay Kit from Molecular Probes (Invitrogen)

Basement Membrane Extract - Phenol Red from R&D Systems

...x High Protein Concentration Basement Membrane Ext...o applications where higher protein concentrations...rength, and elevated levels of tumor augmentation....sistency and controlled protein concentrations to ...

mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis from Molecular Probes (Invitrogen)

Biology Products:

Nitrite Colorimetric Assay Kit from Molecular Probes (Invitrogen)Basement Membrane Extract - Phenol Red from R&D Systems Cultrex High Protein Concentration BME from Trevigen mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis from Molecular Probes (Invitrogen)

Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Canc...( SAN DIEGO Jan. 28 /- Cylene Pharm...)